These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
703 related articles for article (PubMed ID: 28139263)
1. JAK inhibitors in dermatology: The promise of a new drug class. Damsky W; King BA J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263 [TBL] [Abstract][Full Text] [Related]
2. Janus kinase inhibitors in dermatology: A systematic review. Shreberk-Hassidim R; Ramot Y; Zlotogorski A J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015 [TBL] [Abstract][Full Text] [Related]
3. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126 [TBL] [Abstract][Full Text] [Related]
4. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology. Kostovic K; Gulin SJ; Mokos ZB; Ceovic R Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907 [TBL] [Abstract][Full Text] [Related]
5. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology. Cinats A; Heck E; Robertson L Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037 [TBL] [Abstract][Full Text] [Related]
6. JAK-inhibitors in dermatology: current evidence and future applications. Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838 [TBL] [Abstract][Full Text] [Related]
7. Targeting the Janus Kinase Family in Autoimmune Skin Diseases. Howell MD; Kuo FI; Smith PA Front Immunol; 2019; 10():2342. PubMed ID: 31649667 [TBL] [Abstract][Full Text] [Related]
8. Topical Janus kinase inhibitors: A review of applications in dermatology. Hosking AM; Juhasz M; Mesinkovska NA J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776 [TBL] [Abstract][Full Text] [Related]
9. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases. Kahn J; Deverapalli SC; Rosmarin D Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638 [TBL] [Abstract][Full Text] [Related]
10. Janus kinase inhibitors: An innovative treatment for alopecia areata. Park H; Yu DA; Kwon O J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712 [TBL] [Abstract][Full Text] [Related]
11. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions. Fukuyama T; Tschernig T; Qi Y; Volmer DA; Bäumer W Eur J Pharmacol; 2015 Oct; 764():278-282. PubMed ID: 26164790 [TBL] [Abstract][Full Text] [Related]
12. The emerging safety profile of JAK inhibitors in rheumatic disease. Winthrop KL Nat Rev Rheumatol; 2017 Apr; 13(4):234-243. PubMed ID: 28250461 [TBL] [Abstract][Full Text] [Related]
13. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491 [No Abstract] [Full Text] [Related]
14. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications. Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305 [TBL] [Abstract][Full Text] [Related]
15. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis. Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039 [TBL] [Abstract][Full Text] [Related]
16. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Peterson D; Damsky W; King B J Am Acad Dermatol; 2020 Jun; 82(6):e223-e226. PubMed ID: 32278797 [No Abstract] [Full Text] [Related]
17. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis]. Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618 [TBL] [Abstract][Full Text] [Related]
18. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review. Muddebihal A; Khurana A; Sardana K Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306 [TBL] [Abstract][Full Text] [Related]
19. Journal club: New small molecules for atopic dermatitis management. Lefevre MA; Mohme S; Alband N; Nogueira M; Rosell Diaz A; Rodriguez-Lomba E Eur J Dermatol; 2021 Dec; 31(6):849-852. PubMed ID: 35107077 [No Abstract] [Full Text] [Related]
20. JAK inhibitors in chronic plaque psoriasis: What is known so far. Plachouri KM; Georgiou S Drugs Today (Barc); 2020 Feb; 56(2):151-163. PubMed ID: 32163530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]